Allergan (AGN) Offering Possible 21.07% Return Over the Next 26 Calendar Days

Allergan's most recent trend suggests a bullish bias. One trading opportunity on Allergan is a Bull Put Spread using a strike $150.00 short put and a strike $145.00 long put offers a potential 21.07% return on risk over the next 26 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $150.00 by expiration. The full premium credit of $0.87 would be kept by the premium seller. The risk of $4.13 would be incurred if the stock dropped below the $145.00 long put strike price.

The 5-day moving average is moving up which suggests that the short-term momentum for Allergan is bullish and the probability of a rise in share price is higher if the stock starts trending.

The 20-day moving average is moving up which suggests that the medium-term momentum for Allergan is bullish.

The RSI indicator is at 76.03 level which suggests that the stock is neither overbought nor oversold at this time.

To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here


LATEST NEWS for Allergan

CoolSculpting® and Sonja Morgan Talk Bikini Denial Just In Time For Summer
Thu, 21 Mar 2019 13:00:00 +0000
DUBLIN, March 21, 2019 /PRNewswire-PRWeb/ — CoolSculpting, owned by Allergan plc, is partnering once again with television personality on Bravo's “The Real Housewives of New York City”, philanthropist and fashion lifestyle entrepreneur Sonja Morgan to help women prepare for warmer weather and banish their Bikini Denial this summer. Bikini Denial identifies the feeling that many women get when realizing that swimsuit season has snuck up on her and she is not ready to bare it all at the beach or pool until she frees herself of stubborn fat. Visit www.CoolSculpting.com to learn more about how to say “bye-bye” to Bikini Denial and get ready to hit the beach this summer! Consumers can share their own Bikini Denial stories on social media using #BikiniDenial and also enter the Bikini Denial Sweepstakes for a chance to win a free CoolSculpting treatment.

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
Thu, 21 Mar 2019 12:19:12 +0000
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

NASH, Allergies and Beauty Stocks: Invest or Not?
Wed, 20 Mar 2019 19:25:07 +0000
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

Allergan Stock Won’t Benefit From a Breakup, Analyst Says
Wed, 20 Mar 2019 18:55:00 +0000
Share are up 15% year to date, helped by the FDA’s acceptance of new applications for Botox. Still, questions remain about the health of the drugmaker’s pipeline and earnings profile.

10 Stocks on the Rise Heading Into the Second Quarter
Wed, 20 Mar 2019 17:09:19 +0000
March is winding down, and that means the end of the first quarter of 2019. The Q4 earnings season has all but wrapped up. So it's time to prepare for to the second quarter and take a look at some stocks on the rise now.Identifying those stocks is easier said than done though, particularly in this environment. The bulls are determined to hold onto the hard-won gains reaped since the late-December low, but it's becoming more and more difficult. The more the market goes up, the less the buyers are interested in buying in, and trading volume wanes.Nevertheless, there are some stocks on the rise and positioned to continue rallying into the foreseeable future. These names are a trader's best bet at what's often a modestly bullish time of year for the market.InvestorPlace – Stock Market News, Stock Advice & Trading Tips * 5 Cloud Stocks to Help Your Portfolio Fly With that as the backdrop, here's a rundown of the best stocks to buy as we enter Q2. Nielsen Holdings (NLSN)Yes, this is the same Nielsen Holdings (NYSE:NLSN) that measures viewership of television shows. It's more than that, however, the company also measures the efficacy of online and offline marketing campaigns.The past couple of years have been tough for shareholders. NLSN stock fell from a 2016 high near $56 to a mid-2018 low around $21. But the past few months have been progressive. Nielsen shares have recently broken through their 200-day moving average, and bullish crosses of other key moving-average lines are on the radar. Keep in mind, however, that we've seen this headfake before.This movement, along with the stock's forward P/E of 14.6 and the fact that it's going to begin quantifying data regarding Canada's cannabis industry, suddenly makes NLSN an interesting prospect. Amazon.com (AMZN)Like most other names, Amazon.com (NASDAQ:AMZN) stock was up-ended during Q4 of 2018. Unlike most other stocks, however, AMZN didn't produce the rip-roaring rally most other names did in January and February.That's changed this month. Despite the slow start to its rebound, AMZN stock is now on the rise. Shares just fought their way back above the pivotal 200-day moving average line, but have plenty more room to make gains.There's also plenty of bullish fodder, including the company's planned expansion of its grocery business and the ongoing growth of Amazon Web Services. * 4 Unexpected Trade War Stocks That Will Benefit From an End to Tariffs Fun fact: AMZN stock averages a 14% gain during the second calendar quarter of the year. TreeHouse Foods (THS)This stock is exactly a household name, but many households are regular users of its products without even realizing it. TreeHouse Foods (NYSE:THS) makes a variety of private-label foods sold by grocers and restaurants.TreeHouse Foods hasn't exactly been firing on all cylinders lately. The current quarter's per-share profits are projected to fall — as are full-year sales.The company's fiscal results are poised to begin improving in the foreseeable future though, fueled by an industry-wide movement that puts even more focus on so-called 'house brands' of food and condiments. That's why investors have been willing to bid THS stock up nearly 65% since 2018's lows. And there's still a lot of opportunity for more gains thanks to THS stock's 2016/2017 meltdown. Align Technology (ALGN)Align Technology (NASDAQ:ALGN) is the company behind Invisalign's clear braces. Align has been successful for years, but found a sweet spot between price, demand and marketing beginning in 2016. From the end of 2015 to the middle of last year, ALGN stock gained more than 500%. * 7 Invincible Stocks Leading The Bull Market Higher That rally unraveled last year, with Align shares being chopped in half in the face of legal woes surrounding certain patents on its technology… a matter that's still not been firmly decided. Investors are regaining confidence in the company's prospects though. Up more than 40% above its early January low, Align is one of a handful of stocks on the rise moving into Q2. Century Aluminum (CENX)Despite respectable economic growth for the past year and a half, aluminum prices have been falling. Indeed, over the past twelve months, the price of aluminum is down roughly 13%, and still in position to edge lower.It's taken a toll on most of the industry's stocks, including Century Aluminum (NASDAQ:CENX). But, CENX may be on the verge of a turnaround. It's just crossed above several key moving averages, and those moving average lines have just dished out bullish crosses of their own.It also helps to know that Century Aluminum shares, like aluminum prices, have been reliably cyclical. The current shift out of a downtrend and testing the waters of an uptrend looks an awful lot like the rebounds we saw in 2016 and 2013. Pentair (PNR)London-based Pentair (NYSE:PNR) makes a variety of 'smart water' solutions, ranging from pumps to filters to agricultural applications.It's not a high-growth business, but it is a reliably profitable business, even if those profits can be a bit uneven at times. * 7 Financial Stocks to Invest In Today Butt his year should be a decent one. Revenue is projected to improve by 5.3%, and per-shares profits are expected to reach $2.55 — up from last year's $2.35. That progress has translated into new bullishness for PNR shares too. After a hard reversal near the end of 2018, Pentair stock is finally toying with highs above its technical ceiling at $43.60. Cabot Oil & Gas (COG)Energy stocks are inherently volatile, even more so in the current environment. But after tumbling in Q4 alongside falling crude prices, they're looking like good bets again.Cabot Oil & Gas (NYSE:COG) is shaping up to one of the top prospects from the energy sector. Investors have to zoom out to a weekly chart to fully appreciate it, but shares have slowly shifted out of a downtrend and into an uptrend over the course of the past several months. One more good gain could complete the breakout effort, which has pushed COG stock past all key moving averages.The kicker: COG averages a Q2 gain of 7.4%. Allergan (AGN)Allergan (NYSE:AGN) has been a poor performer since peaking in the middle of 2015. In fact, AGN stock is down more than 50% from that high, and hit a new 52-week low in December. It's been a challenging name to own, to say the least. * 5 Dow Jones Stocks Coming to Life Yet, a shocking number of hedge funds and institutional investors now own a beaten-down Allergan. As Sanford C. Bernstein's pharmaceutical analyst Ronny Gal explained last month, Allergan has become a very popular holding, partially because it has buyout potential and partially because the company is just doing well. Additionally, Gal is excited about the value creation that could stem from an increasingly likely breakup of Allergan's different arms. Molson Coors Brewing (TAP)Molson Coors Brewing (NYSE:TAP) has been in a downtrend since the middle of 2016 and reached new multi-year lows in December of last year. TAP stock has been toying with a reversal since October though — an effort marked by a lot of volatility and several big countermoves. The bulls are testing the waters, even if they're not making a lot of not progress. But one more good 'umph' could get — and keep — TAP shares above key moving averages and break through the technical ceiling that's formed near $67.00.The calendar is working in TAP stock's favor as well. Molson Coors shares gain an average of 3% during Q2, but keep on moving through September to log an and additional average gain of about 4% during Q3. Old Republic International (ORI)Finally, add Old Republic International (NYSE:ORI) to your list stocks on the rise as the Q2 begins.Like most insurance stocks, ORI has had its recent ups and downs. Unlike most of its peers though, Old Republic is making reliable net progress, taking two steps forward for every one step back. ORI has been weak since September, but appears to be pushing off of a support line that extends all the way back to early 2015. * Top 7 Service Sector Stocks That Will Pay You to Own Them Analysts agree there are higher highs in store. Although ORI is not widely followed by professionals, the ones that do keep tabs on it collectively say the stock's worth $24 per share, which would put it near the upper boundary of the trading range that's been in place since 2015.As of this writing, James Brumley held a long position in Treehouse Foods and Nielsen Holdings . You can learn more about James at his site, jamesbrumley.com, or follow him on Twitter, at @jbrumley. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 7 Invincible Stocks Leading The Bull Market Higher * 5 Dow Jones Stocks Coming to Life * 7 of the Best High-Yield Funds for 2019 and Beyond Compare Brokers The post 10 Stocks on the Rise Heading Into the Second Quarter appeared first on InvestorPlace.

Be Sociable, Share!

Related Posts

 

MarketTamer is not an investment advisor and is not registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory Authority. Further, owners, employees, agents or representatives of MarketTamer are not acting as investment advisors and might not be registered with the U.S. Securities and Exchange Commission or the Financial Industry Regulatory.


This company makes no representations or warranties concerning the products, practices or procedures of any company or entity mentioned or recommended in this email, and makes no representations or warranties concerning said company or entity’s compliance with applicable laws and regulations, including, but not limited to, regulations promulgated by the SEC or the CFTC. The sender of this email may receive a portion of the proceeds from the sale of any products or services offered by a company or entity mentioned or recommended in this email. The recipient of this email assumes responsibility for conducting its own due diligence on the aforementioned company or entity and assumes full responsibility, and releases the sender from liability, for any purchase or order made from any company or entity mentioned or recommended in this email.


The content on any of MarketTamer websites, products or communication is for educational purposes only. Nothing in its products, services, or communications shall be construed as a solicitation and/or recommendation to buy or sell a security. Trading stocks, options and other securities involves risk. The risk of loss in trading securities can be substantial. The risk involved with trading stocks, options and other securities is not suitable for all investors. Prior to buying or selling an option, an investor must evaluate his/her own personal financial situation and consider all relevant risk factors. See: Characteristics and Risks of Standardized Options. The www.MarketTamer.com educational training program and software services are provided to improve financial understanding.


The information presented in this site is not intended to be used as the sole basis of any investment decisions, nor should it be construed as advice designed to meet the investment needs of any particular investor. Nothing in our research constitutes legal, accounting or tax advice or individually tailored investment advice. Our research is prepared for general circulation and has been prepared without regard to the individual financial circumstances and objectives of persons who receive or obtain access to it. Our research is based on sources that we believe to be reliable. However, we do not make any representation or warranty, expressed or implied, as to the accuracy of our research, the completeness, or correctness or make any guarantee or other promise as to any results that may be obtained from using our research. To the maximum extent permitted by law, neither we, any of our affiliates, nor any other person, shall have any liability whatsoever to any person for any loss or expense, whether direct, indirect, consequential, incidental or otherwise, arising from or relating in any way to any use of or reliance on our research or the information contained therein. Some discussions contain forward looking statements which are based on current expectations and differences can be expected. All of our research, including the estimates, opinions and information contained therein, reflects our judgment as of the publication or other dissemination date of the research and is subject to change without notice. Further, we expressly disclaim any responsibility to update such research. Investing involves substantial risk. Past performance is not a guarantee of future results, and a loss of original capital may occur. No one receiving or accessing our research should make any investment decision without first consulting his or her own personal financial advisor and conducting his or her own research and due diligence, including carefully reviewing any applicable prospectuses, press releases, reports and other public filings of the issuer of any securities being considered. None of the information presented should be construed as an offer to sell or buy any particular security. As always, use your best judgment when investing.